Pure Hospitality Solutions Inc (OTCMKTS:PNOW) released a letter to its shareholders wherein it stated that since the start of this year, they have taken several measures to develop and manage itself for future growth.
It indicates that the company can take full benefits of the amazing development the core product, Oveedia has achieved since the preliminary beta launch in 2015. The management expects this progress to gain pace as Central American tourism starts to get increased market share within the fast growing Latin American Travel Market.
The highlights
Pure Hospitality management shifted their energies and resources on capitalizing on strengths in hospitality, social media and online technology. From the time they took this step, they resulted in a corporate evolution, which is projected to create long-term value for the firm. Becoming a major player in online travel industry is vital in the accomplishing of original mandate.
This objective is attainable as Pure Hospitality was fortunate enough to seek a niche within the LATM industry. From this point, the company can enter into a booming travel operation as an OTA, and eventually leverage success, into other arenas of hospitality.
The scenario
Pure Hospitality management sole focus is on advancing a Latin–centric online travel agency, that becomes the major travel center for an underserved region, but booming market, in both the Latin nations of the Caribbean and the Central America.
Mr. Barry Diller, who acquired Expedia in 2001, was mentioned in Scott McCartney’s article, stating that they were going to manufacture more locations for people to go. The industry has been growing faster, and it is because of the people capabilities to get information. There is considerable growth in Latin American tourism. Mexico is indeed bustling; South America too, and both are major contributors to almost $90 billion market in LATAM’s tourism industry.
OXIS International, Inc. (OTCMKTS:OXIS) Banking On OXS-1550 To Set It On The Map On CancerTreatments
Amidst all the developments in the medical space, OXIS International, Inc. (OTCMKTS:OXIS) could hold the key to curing cancer given its robust pipeline of drugs. The biotechnology company appears to be one of the most undervalued companies given that it has already made crucial strides on the development and commercialization of innovative therapies for the treatment of cancer.
Spearheading the company’s next generation of cancer initiatives is its lead drug candidate OXS-1550. The drug is currently undergoing a Phase 1/ Phase 2 trial at the university of Minnesota Masonic Cancer Center for the treatment of leukemia having demonstrated success in early human clinical trials.
What separates OXS-1550 from other cancer therapy is the fact that it is designed to search and destroy cancer cells. Should the clinical trials turn out positive the drug could end up acting as a powerful alternative to chemotherapy given its reduced toxicity levels.
